

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 28, 2003, 18:21:02 ; Search time 43.2727 Seconds
(without alignments)
51.353 Million cell updates/sec

Title: US-09-743-225-9

Perfect score: 73

Sequence: 1 KDRATGTHDGGXA 14

Scoring table: BLOSUM62

Gapop 10.0 ,Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_19Jun03.*

1: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1980.DAT.*
2: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1981.DAT.*
3: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1982.DAT.*
4: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1983.DAT.*
5: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1984.DAT.*
6: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1985.DAT.*
7: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1986.DAT.*
8: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1987.DAT.*
9: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1988.DAT.*
10: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1989.DAT.*
11: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1990.DAT.*
12: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1991.DAT.*
13: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1992.DAT.*
14: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1993.DAT.*
15: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1994.DAT.*
16: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1995.DAT.*
17: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1996.DAT.*
18: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1997.DAT.*
19: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1998.DAT.*
20: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA1999.DAT.*
21: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2000.DAT.*
22: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2001.DAT.*
23: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2002.DAT.*
24: /SIDSI/gcgdata/geneseq/geneseq-emb1/AA2003.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	71	97.3	14	21 AAY69260	Monopeptide which
2	62	84.9	11	21 AAY69270	Cyclic peptide whi
3	56	76.7	12	21 AAB17993	Beta-2GPI Ab bindi
4	56	76.7	12	23 AAB73364	Exemplary pharmaco
5	56	76.7	145	16 AAR75003	Human beta-2 glyco
6	56	76.7	207	16 AAR75002	Human beta-2 glyco
7	56	76.7	248	16 AAR74999	Human beta-2 glyco
8	56	76.7	266	16 AAR75001	Human beta-2 glyco
9	56	76.7	326	16 AAR74998	Human beta-2 glyco

10	56	76.7	326	21 AAY44429	Human beta-2 glyco
11	56	76.7	345	24 ABR48505	Human Apolipoprote
12	50	68.5	10	21 AAB17992	Beta-2GPI Ab bindi
13	50	68.5	10	23 AAB73363	Exemplary pharmaco
14	44	60.3	785	21 AAG52220	Humicola insolens
15	44	60.3	785	22 AAG65578	H. insolens DSM 18
16	42	57.5	1674	20 AAY06199	Maize endosperm st
17	42	57.5	1674	21 ABA49305	Maize starch synth
18	41	56.2	95	23 ABP09333	Human ORFX protein
19	40	54.8	718	23 ABG80348	Clostridium diffi
20	40	54.8	719	23 AAG79241	Amino acid sequenc
21	40	54.8	719	23 ABG80349	Clostridium diffi
22	40	54.8	719	23 ABG80352	Clostridium diffi
23	40	54.8	719	23 ABG80353	Clostridium diffi
24	40	54.8	719	23 AAU12037	Clostridium diffi
25	39	53.4	14	22 ABB56636	Human SNP related
26	39	53.4	102	22 AAM84388	Human Immune/haema
27	39	53.4	258	24 ABR48467	Human Armapoptin.
28	39	53.4	453	22 AAU28175	Novel human secret
29	39	53.4	453	22 AAG67135	Amino acid sequenc
30	39	53.4	453	22 AAG67208	Amino acid sequenc
31	39	53.4	453	22 AAM93332	Human polypeptide,
32	39	53.4	518	24 ABP77203	N. gonorrhoeae ami
33	39	53.4	664	22 AAB20000	Arabidopsis acyl-C
34	39	53.4	1039	22 ABG15145	Novel human diagno
35	38	52.1	283	21 AAY88050	C. versicolor stre
36	38	52.1	283	21 AAY88051	C. versicolor stre
37	38	52.1	480	23 AAU82978	C. albicans BPR2 p
38	38	52.1	531	23 ABP73319	Candida albicans e
39	38	52.1	794	24 ABJ25779	Aspergillus fumiga
40	38	52.1	794	24 ABJ26379	Aspergillus fumiga
41	37	50.7	114	22 AAU46546	Propionibacterium
42	37	50.7	188	23 AAU69559	Human G protein-co
43	37	50.7	295	23 AAG98037	Mutant haloalkane
44	37	50.7	537	23 ABP28881	Streptococcus poly
45	37	50.7	3636	21 AAG47201	Arabidopsis thalia

ALIGNMENTS

RESULT 1
AAY69260
ID AAY69260 standard; peptide; 14 AA.
XX
XX AAY69260;
AC
AC AAY69260;
DT 30-MAY-2000 (first entry)
XX
XX Monopeptide which inhibits anti-beta-2-glycoprotein 1 antibodies.
DE
DE Anti-beta-2-glycoprotein 1 antibody; anti-B2GPI antibody;
KW anti-phospholipid syndrome; anti-phospholipid antibody;
KW pregnancy complication; thrombosis; coagulation dysregulation.
XX
XX Synthetic.
OS
XX Key Location/Qualifiers
FH Modified-site 13
FT /note= "FmocLys(Fmoc)-OH"
XX
XX WO200001729-A2.
PN
XX
XX 13-JAN-2000.
PD
XX
XX 06-JUL-1999; 99WO-IL00366.
PF
XX
XX 07-JUL-1998; 98IL-0125262.
PR
XX
XX (YEDA) YEDA RES & DEV CO LTD.
PA
XX
XX Blank M, Cabilly S, Shoenfeld Y, Katchalski-Katzir E;
PI
XX

DR WPI; 2000-182105/16.
 XX Novel synthetic peptides that inhibit anti-beta-2-glycoprotein 1
 PT antibodies, useful for diagnosis and treatment of anti-phospholipid
 PT syndrome in humans
 XX
 XX Disclosure; Page 13; 58pp; English.
 XX
 CC The present sequence represents a synthetic peptide which is capable
 CC of inhibiting the biological activity of anti-beta-2-glycoprotein 1
 CC (B2GPI) monoclonal antibodies in vitro and of inhibiting in vivo
 CC induction of experimental anti-phospholipid syndrome in mice by
 CC anti-B2GPI monoclonal antibodies. The peptides are used for diagnosis
 CC and treatment of anti-phospholipid syndrome. They may also be used
 CC for the diagnosis of anti-phospholipid antibodies with different
 CC pathogenic biofunctions which may correlate with either pregnancy
 CC complications, thrombosis or coagulation dysregulation.
 XX
 XX SQ Sequence 14 AA;
 Query Match 97.3%; Score 71; DB 21; Length 14;
 Best Local Similarity 100.0%; Pred. No. 2.3e-06; Indels 0; Gaps 0;
 Matches 14; Conservative 0; Mismatches 0;
 QY 1 KDKATFGTHDGGXA 14
 Db 1 KDKATFGTHDGGXA 14
 RESULT 2
 AAY69270
 ID AAY69270 standard; peptide; 11 AA.
 AC AAY69270;
 XX
 XX 30-MAY-2000 (first entry)
 DE Cyclic peptide which inhibits anti-beta-2-glycoprotein 1 antibodies.
 XX
 XX Anti-beta-2-glycoprotein 1 antibody; anti-B2GPI antibody; cyclic;
 KW anti-phospholipid syndrome; anti-phospholipid antibody;
 KW pregnancy complication; thrombosis; coagulation dysregulation.
 XX
 XX Synthetic.
 OS
 XX WO200001729-A2.
 PN
 XX 13-JAN-2000.
 PD
 XX 06-JUL-1999; 99WO-1100366.
 PF
 XX 07-JUL-1998; 98IL-0125262.
 PR
 XX (YEDA) YEDA RES & DEV CO LTD.
 PA
 XX Blank M, Cabilly S, Shoenfeld Y, Katchalski-Katzir E;
 PI WPI; 2000-182105/16.
 DR
 XX Novel synthetic peptides that inhibit anti-beta-2-glycoprotein 1
 PT antibodies, useful for diagnosis and treatment of anti-phospholipid
 PT syndrome in humans
 XX
 XX Claim 4; Page 38; 58pp; English.
 PS
 XX The present sequence represents a synthetic peptide which is capable
 CC of inhibiting the biological activity of anti-beta-2-glycoprotein 1
 CC (B2GPI) monoclonal antibodies in vitro and of inhibiting in vivo
 CC induction of experimental anti-phospholipid syndrome in mice by
 CC anti-B2GPI monoclonal antibodies. The peptides are used for diagnosis
 CC and treatment of anti-phospholipid syndrome. They may also be used
 CC for the diagnosis of anti-phospholipid antibodies with different
 CC pathogenic biofunctions which may correlate with either pregnancy
 CC complications, thrombosis or coagulation dysregulation.

CC complications, thrombosis or coagulation dysregulation.
 XX
 XX SQ Sequence 11 AA;
 Query Match 84.9%; Score 62; DB 21; Length 11;
 Best Local Similarity 100.0%; Pred. No. 7.8e-05; Indels 0; Gaps 0;
 Matches 11; Conservative 0; Mismatches 0;
 QY 1 KDKATFGTHDG 11
 Db 1 KDKATFGTHDG 11
 RESULT 3
 AAB17993
 ID AAB17993 standard; Peptide; 12 AA.
 AC AAB17993;
 XX
 XX 31-OCT-2000 (first entry)
 DT
 XX Beta-2GPI Ab binding peptide sequence SEQ ID NO:1105.
 DE
 XX Modified peptide; therapeutic agent; fusion; Fc domain; cancer;
 KW autoimmune disease; cytostatic; antiasthmatic; thrombolytic; VEGF;
 KW immunosuppressive; EPO; TPO; CTLA4; mimetic; IL-1; TNF; antagonist;
 KW MMP; inhibitor; erythropoietin; thrombopoietin; interleukin 1;
 KW cytotoxic T cell lymphocyte antigen 4; tumour necrosis factor;
 KW vascular endothelial growth factor; matrix metalloproteinase;
 KW asthma; thrombosis; pharmaceutical.
 KW
 OS Synthetic.
 OS
 XX WO200024782-A2.
 PN
 XX 04-MAY-2000.
 PD
 XX 25-OCT-1999; 99WO-US25044.
 PF
 XX 23-OCT-1998; 98US-0105371.
 PR
 XX 22-OCT-1999; 99US-0428082.
 PR
 XX (AMGE-) AMGEN INC.
 PA
 XX Feige U, Liu C, Cheetham J, Boone TC;
 PI WPI; 2000-350702/30.
 DR
 XX Novel composition of matter comprising an Fc domain and
 PT pharmacologically active peptides, useful for treating cancer and
 PT autoimmune diseases
 XX
 XX Claim 39; Page 600; 608pp; English.
 PS
 XX The present invention describes composition of matter (I) comprising an
 CC Fc domain, pharmacologically active peptides, and linkers. Where (I) is:
 CC (X1)a-F1-(X2)b, where: F1 = an Fc domain; X1 and X2 = are each
 CC independently selected from -(L1)c-P1, -(L1)c-P1-(L2)d-P2,
 CC -(L1)c-P1-(L2)d-P2-(L3)e-P3, or -(L1)c-P1-(L2)d-P2-(L3)e-P3-(L4)f-P4
 CC where P1, P2, P3, and P4 = are each independently sequences of
 CC pharmacologically active peptides; L1, L2, L3, and L4 = are each
 CC independently linkers; and a, b, c, d, e, and f = are each independently
 CC 0 or 1, provided that at least 1 of a and b is 1. The composition can
 CC have cytostatic, antiasthmatic, thrombolytic and immunosuppressive
 CC activities. DNAs, vectors and host cells from the present invention can
 CC be used for producing pharmaceutical compositions. The compositions are
 CC useful for treating cancer, asthma, thrombosis, or autoimmune diseases.
 CC The use of an Fc domain (rather than a Fab domain) can provide a longer
 CC half-life or incorporate functions such as Fc receptor binding, protein
 CC A binding, complement fixation, and possibly placental transfer. AAB69443
 CC to AAB69526 and AAB16955 to AAB18003 represent nucleotide and amino acid
 CC sequences used in the exemplification of the present invention.
 XX

SQ Sequence 12 AA;
 Query Match 76.7%; Score 56; DB 21; Length 12;
 Best Local Similarity 90.9%; Pred. No. 0.0011;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 KDRATFGTHDG 11
 ||||| |||
 DB 1 KDRATFGCHDG 11

RESULT 4
 ABB73364
 ID ABB73364 standard; Peptide; 12 AA.
 XX AC ABB73364;
 XX DT 05-APR-2002 (first entry)
 XX EXemplary pharmacologically active peptide SEQ ID NO:1103.
 XX DE Modified peptide; mimetic; Fc domain; fusion; immunoglobulin G; IgG;
 KW EPO; erythropoietin; TPO; tumour necrosis factor alpha inhibitor;
 KW TNF-alpha inhibitor; interleukin 1 antagonist; IL-1 antagonist; TNF;
 KW TPO mimetic peptide; EPO mimetic peptide; EMP; VEGF antagonist;
 KW MMP inhibitor; antiinflammatory; antitumour; immunosuppressive;
 KW cytosstatic; antirheumatic; antiarthritis; antidiabetic; ophthalmological;
 KW antianemic; anorectic; antifertility; haemostatic; dermatological;
 KW neuroprotective; inflammatory disease; autoimmune disease; tumour growth;
 KW cancer; rheumatoid arthritis; diabetic retinopathy; infertility; obesity;
 KW sleep disorder; neurological degenerative disease; anaemia;
 KW thrombocytopaenia; metastatic tumour; systemic lupus erythematosus;
 KW Fanconi's syndrome.
 XX OS Synthetic.
 XX WO200183525-A2.
 XX 08-NOV-2001.
 XX 02-MAY-2001; 2001WO-US14310.
 XX 03-MAY-2000; 2000US-0563286.
 XX (AMGE-) AMGEN INC.
 XX Felge U, Liu C, Cheetham JC, Boone TC, Gudas JM;
 WPI; 2002-130313/17.
 Novel vehicle-peptide molecule or its multimers useful for treating
 inflammatory and autoimmune diseases, cancer, rheumatoid arthritis,
 diabetic retinopathy, obesity, sleep disorders and infertility
 Claim 39; Page 62; 176pp; English.

The present invention describes a vehicle-peptide molecule (I) or its
 multimers. (I) can have antiinflammatory, antitumour, immunosuppressive,
 cytosstatic, antirheumatic, antiarthritis, antidiabetic, ophthalmological,
 antianemic, anorectic, antifertility, haemostatic, dermatological and
 neuroprotective activities. (I) can be used as a therapeutic or
 prophylactic agent as well as for screening purposes. (I) is useful for
 diagnosing diseases characterised by dysfunction of their associated
 protein of interest, for identifying normal or abnormal proteins of
 interest, as a part of diagnostic kit to detect the presence of their
 proteins of interest in a biological sample. Additionally, (I) is useful
 for treating inflammatory and autoimmune diseases, tumour growth, cancer,
 rheumatoid arthritis, diabetic retinopathy, obesity, sleep disorders,
 infertility, and neurological degenerative diseases. (I), comprising
 EPO-mimetic compounds are useful for treating disorders characterised by
 low red blood cell levels such as anaemia. The TPO-mimetic comprising
 compounds are useful for treating conditions that involve an existing
 megakaryocyte/platelet deficiency or an expected megakaryocyte/platelet

CC deficiency, such as thrombocytopaenia, aplastic anaemia, metastatic
 CC tumour which result in thrombocytopaenia, systemic lupus erythematosus,
 CC and Fanconi's syndrome. ABB72403 to ABB73426 and ABL35695 to ABL35777
 CC represent amino acid and nucleic acid sequences used in the
 CC exemplification of the present invention.

QY 1 KDRATFGTHDG 11
 ||||| |||
 DB 1 KDRATFGCHDG 11

Query Match 76.7%; Score 56; DB 23; Length 12;
 Best Local Similarity 90.9%; Pred. No. 0.0011;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 KDRATFGTHDG 11
 ||||| |||
 DB 1 KDRATFGCHDG 11

RESULT 5
 AAR75003
 ID AAR75003 standard; protein; 145 AA.
 XX AC AAR75003;
 XX DT 18-JAN-1996 (first entry)
 XX Human beta-2 glycoprotein domains IV-V.
 KW Human beta-2 glycoprotein; domains IV-V; antiphospholipid antibodies;
 KW reagent; assay; diagnosis; autoimmune; infectious diseases.
 XX OS Homo sapiens.
 XX Key Location/Qualifiers
 FH Disulfide-bond 5..48
 FT Disulfide-bond 34..60
 FT Disulfide-bond 64..115
 FT Disulfide-bond 100..125
 FT Disulfide-bond 107..145
 XX WO9514231-A1.
 XX 26-MAY-1995.
 XX 15-NOV-1994; 94WO-JP01929.
 XX 16-NOV-1993; 93JP-0309874.
 XX (YAMA-) YAMASA CORP.
 XX Igarashi M, Igarashi Y, Koike T, Matsuura E, Nagae H;
 WPI; 1995-200487/26.
 Assay and typing of anti-phospholipid antibodies - using peptide
 containing the IV domain of beta-2 glyco:protein
 Example; Fig 6; 70pp; Japanese.

AAR75003 is the human beta-2 glycoprotein domains IV-V, it can be
 used as a reagent (prefer. immobilised on a suitable carrier) in
 an immunoassay for antiphospholipid antibodies in biological
 samples. The assay allows the rapid and accurate diagnosis of
 CC syndromes involving antiphospholipid antibodies, and can
 CC discriminate between autoimmune and infectious diseases.

QY 1 KDRATFGTHDG 11
 ||||| |||

Query Match 76.7%; Score 56; DB 16; Length 145;
 Best Local Similarity 90.9%; Pred. No. 0.02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 KDRATFGTHDG 11
 ||||| |||

```

Db      27 KDKATFGCHDG 37

RESULT 6
AAR75002
ID AAR75002 standard; protein; 207 AA.
AC AAR75002;
AD 18-JAN-1996 (first entry)
DE Human beta-2 glycoprotein domains III-V.
XX Human beta-2 glycoprotein; domains III-V; antiphospholipid antibodies;
KW reagent; assay; diagnosis; autoimmune; infectious diseases.
XX Homo sapiens.
XX Key Location/Qualifiers
FH Disulfide-bond 4..50
FT Disulfide-bond 36..62
FT Disulfide-bond 67..110
FT Disulfide-bond 96..122
FT Disulfide-bond 126..177
FT Disulfide-bond 162..187
FT Disulfide-bond 169..207
XX WO9514231-A1.
XX 26-MAY-1995.
XX 15-NOV-1994; 94WO-JP01929.
XX 16-NOV-1993; 93JP-0309874.
XX (YAMA-) YAMASA CORP.
XX Igarashi M, Igarashi Y, Koike T, Matsuura E, Nagae H;
XX WPI; 1995-200487/26.
XX Assay and typing of anti:phospholipid antibodies - using peptide
XX containing the IV domain of beta-2 glyco:protein
XX Example; Fig 5; 70pp; Japanese.
XX AAR75002 is the human beta-2 glycoprotein domains III-V, it can be
XX used as a reagent (pref. immobilised on a suitable carrier) in
XX an immunoassay for antiphospholipid antibodies in biological
XX samples. The assay allows the rapid and accurate diagnosis of
XX syndromes involving antiphospholipid antibodies, and can
XX discriminate between autoimmune and infectious diseases.
XX Sequence 207 AA;
Query Match 76.7%; Score 56; DB 16; Length 207;
Best Local Similarity 90.9%; Pred. No. 0.031;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 KDKATFGTHDG 11
DB 89 KDKATFGCHDG 99

RESULT 7
AAR74999
ID AAR74999 standard; protein; 248 AA.
AC AAR74999;
AD 18-JAN-1996 (first entry)
DE Human beta-2 glycoprotein domains I-IV.
XX Human beta-2 glycoprotein; domains I-IV; antiphospholipid antibodies;
KW reagent; assay; diagnosis; autoimmune; infectious diseases.
XX Homo sapiens.
XX Key Location/Qualifiers
FH Disulfide-bond 5..45
FT Disulfide-bond 31..58
FT Disulfide-bond 63..109
FT Disulfide-bond 95..121
XX WO9514231-A1.
XX 26-MAY-1995.
XX 15-NOV-1994; 94WO-JP01929.
XX 16-NOV-1993; 93JP-0309874.
XX (YAMA-) YAMASA CORP.
XX Igarashi M, Igarashi Y, Koike T, Matsuura E, Nagae H;
XX WPI; 1995-200487/26.
XX Assay and typing of anti:phospholipid antibodies - using peptide
XX containing the IV domain of beta-2 glyco:protein
XX Example; Fig 5; 70pp; Japanese.
XX AAR75002 is the human beta-2 glycoprotein domains III-V, it can be
XX used as a reagent (pref. immobilised on a suitable carrier) in
XX an immunoassay for antiphospholipid antibodies in biological
XX samples. The assay allows the rapid and accurate diagnosis of
XX syndromes involving antiphospholipid antibodies, and can
XX discriminate between autoimmune and infectious diseases.
XX Sequence 207 AA;
Query Match 76.7%; Score 56; DB 16; Length 207;
Best Local Similarity 90.9%; Pred. No. 0.031;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 KDKATFGTHDG 11
DB 89 KDKATFGCHDG 99

RESULT 8
AAR75001
ID AAR75001 standard; protein; 266 AA.
AC AAR75001;
AD 18-JAN-1996 (first entry)
DE Human beta-2 glycoprotein domains II-V.
XX Human beta-2 glycoprotein; domains II-V; antiphospholipid antibodies;
KW reagent; assay; diagnosis; autoimmune; infectious diseases.
XX Homo sapiens.
XX Key Location/Qualifiers
FH Disulfide-bond 5..45
FT Disulfide-bond 31..58
FT Disulfide-bond 63..109
FT Disulfide-bond 95..121
XX WO9514231-A1.
XX 26-MAY-1995.
XX 15-NOV-1994; 94WO-JP01929.
XX 16-NOV-1993; 93JP-0309874.
XX (YAMA-) YAMASA CORP.
XX Igarashi M, Igarashi Y, Koike T, Matsuura E, Nagae H;
XX WPI; 1995-200487/26.
XX Assay and typing of anti:phospholipid antibodies - using peptide
XX containing the IV domain of beta-2 glyco:protein
XX Example; Fig 2; 70pp; Japanese.
XX AAR74999 is the human beta-2 glycoprotein domains I-IV, it can be
XX used as a reagent (pref. immobilised on a suitable carrier) in
XX an immunoassay for antiphospholipid antibodies in biological
XX samples. The assay allows the rapid and accurate diagnosis of
XX syndromes involving antiphospholipid antibodies, and can
XX discriminate between autoimmune and infectious diseases.
XX Sequence 248 AA;
Query Match 76.7%; Score 56; DB 16; Length 248;
Best Local Similarity 90.9%; Pred. No. 0.036;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 KDKATFGTHDG 11
DB 208 KDKATFGCHDG 218

```


XX New isolated domain 1 beta-2 GPI polypeptides, used for inhibiting
PT antiphospholipid antibodies for treating, e.g. thrombosis -
XX
XX Claim 1; Fig 1; 158pp; English.
XX
XX The present sequence is human beta-2 glycoprotein, a phospholipid binding
CC serum protein. GPI proteins bind to and inhibits beta-2 GPI-dependent
CC antiphospholipid antibodies. They are useful as toleragens when they bind
CC to the antibodies at the surface of a B cell and triggers B cell anergy.
XX The polypeptides and mimetics can be used for treating disorders
CC associated with beta-2GPI-dependent aPL-associated pathologies, e.g.
CC thrombosis, recurrent foetal loss, thrombocytopenia or autoimmune
CC diseases such as systemic lupus erythematosus. The polypeptides can also
CC be used to detect and purify antibodies. They can also be used in
CC coagulation assays.
XX
XX Sequence 326 AA;
XX
XX Query Match 76.7%; Score 56; DB 21; Length 326;
XX Best Local Similarity 90.9%; Pred. No. 0.052;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 1 KDKATFGTHDG 11
XX ||||| |||
XX 208 KDKATFGCHDG 218
XX
XX RESULT 11
XX ABR48505
XX ID ABR48505 standard; Protein; 345 AA.
XX
XX AC ABR48505;
XX
XX DT 13-JUN-2003 (first entry)
XX
XX DE Human Apolipoprotein H, NAPHO.
XX
XX KW Human; GENSET; therapeutic; therapy.
XX
XX OS Homo sapiens.
XX
XX PN WO200294864-A2.
XX
XX PD 28-NOV-2002.
XX
XX PF 06-AUG-2001; 2001WO-IB01715.
XX
XX PR 25-MAY-2001; 2001US-293574P.
XX
XX PR 15-JUN-2001; 2001US-298698P.
XX
XX PR 29-JUN-2001; 2001US-302277P.
XX
XX PR 13-JUL-2001; 2001US-305456P.
XX
XX (GEST) GENSET.
XX
XX PI Bejanin S, Tanaka H;
XX
XX DR WPI; 2003-129412/12.
XX
XX DR N-PSDB; ACC51112.
XX
XX PT New GENSET polynucleotides and polypeptides, useful for preparing a
XX composition for treating GENSET-related disorders and as reagents in
XX assays to quantitatively determined levels of GENSET expression in
XX biological samples -
XX
XX Claim 2; Page 496-497; 505pp; English.
XX
XX The present invention relates to novel human GENSET coding sequences
XX (ACC51060-ACC51115) and proteins (ABR48453-ABR48508). The GENSET
XX sequences are useful for preparing a composition for treating
XX GENSET-related disorders. They can also be used as markers for tissues in
XX which the corresponding protein is preferentially expressed, as molecular
XX weight markers on Southern gels, as chromosome markers or tags to

CC identify chromosomes, and as reagents in assays to quantitatively
CC determined levels of GENSET expression in biological samples.
XX
XX Sequence 345 AA;
XX
XX Query Match 76.7%; Score 56; DB 24; Length 345;
XX Best Local Similarity 90.9%; Pred. No. 0.056;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 1 KDKATFGTHDG 11
XX ||||| |||
XX 227 KDKATFGCHDG 237
XX
XX RESULT 12
XX AAB17992
XX ID AAB17992 standard; Peptide; 10 AA.
XX
XX AC AAB17992;
XX
XX DT 31-OCT-2000 (first entry)
XX
XX DE Beta-2GPI Ab binding peptide sequence SEQ ID NO:1104.
XX
XX KW Modified peptide; therapeutic agent; fusion; Fc domain; cancer;
XX autoimmune disease; cytostatic; antiasthmatic; thrombolytic; VEGF;
XX immunosuppressive; EPO; TPO; CTLA4; mimetic; IL-1; TNF; antagonist;
XX MMP; inhibitor; erythropoietin; thrombopoietin; interleukin 1;
XX cytotoxic T cell lymphocyte antigen 4; tumour necrosis factor;
XX vascular endothelial growth factor; matrix metalloproteinase;
XX asthma; thrombosis; pharmaceutical.
XX
XX OS Synthetic.
XX
XX PN WO200024782-A2.
XX
XX PD 04-MAY-2000.
XX
XX PF 25-OCT-1999; 99WO-US25044.
XX
XX PR 23-OCT-1998; 98US-0105371.
XX
XX PR 22-OCT-1999; 99US-0428082.
XX
XX PA (AMGE-) AMGEN INC.
XX
XX PI Feige U, Liu C, Cheetham J, Boone TC;
XX
XX DR WPI; 2000-350702/30.
XX
XX PT Novel composition of matter comprising an Fc domain and
XX pharmacologically active peptides, useful for treating cancer and
XX autoimmune diseases -
XX
XX Claim 39; Page 600; 608pp; English.
XX
XX The present invention describes composition of matter (I) comprising an
XX Fc domain, pharmacologically active peptides, and linkers. Where (I) is:
XX (X1)a-F1-(X2)b, where: F1 = an Fc domain; X1 and X2 = are each
XX independently selected from -(L1)c-P1, -(L1)c-P1-(L2)d-P2,
XX -(L1)c-P1-(L2)d-P2-(L3)e-P3, or -(L1)c-P1-(L2)d-P2-(L3)e-P3-(L4)f-P4
XX where P1, P2, P3, and P4 = are each independently sequences of
XX pharmacologically active peptides; L1, L2, L3, and L4 = are each
XX independently linkers; and a, b, c, d, e, and f = are each independently
XX 0 or 1, provided that at least 1 of a and b is 1. The composition can
XX have cytostatic, antiasthmatic, thrombolytic and immunosuppressive
XX activities. DNAs, vectors and host cells from the present invention can
XX be used for producing pharmaceutical compositions. The compositions are
XX useful for treating cancer, asthma, thrombosis, or autoimmune diseases.
XX The use of an Fc domain (rather than a Fab domain) can provide a longer
XX half-life or incorporate functions such as Fc receptor binding, protein
XX A binding, complement fixation, and possibly placental transfer. AAA69443
XX to AAA69526 and AAB18955 to AAB18903 represent nucleotide and amino acid
XX sequences used in the exemplification of the present invention.

XX SQ Sequence 10 AA;
 Query Match 68.5%; Score 50; DB 21; Length 10;
 Best Local Similarity 90.0%; Pred. No. 0.011;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 KDKATFGTHD 10
 ||||| ||
 Db 1 KDKATFGCHD 10

RESULT 13
 ABB73363
 ID ABB73363 standard; Peptide; 10 AA.
 XX AC ABB73363;
 DT 05-APR-2002 (first entry)
 XX Exemplary pharmacologically active peptide SEQ ID NO:1102.

XX Modified peptide; mimetic; Fc domain; fusion; immunoglobulin G; IgG;
 KW EPO; erythropoietin; TPO; tumour necrosis factor alpha inhibitor;
 KW TNF-alpha inhibitor; interleukin 1 antagonist; IL-1 antagonist; TNP;
 KW TPO mimetic peptide; EPO mimetic peptide; EMP; VEGF antagonist;
 KW MMP inhibitor; antiinflammatory; antitumour; immunosuppressive;
 KW cytostatic; antirheumatic; antiarthritis; antidiabetic; ophthalmological;
 KW antianemic; anorectic; antifertility; haemostatic; dermatological;
 KW neuroprotective; inflammatory disease; autoimmune disease; tumour growth;
 KW cancer; rheumatoid arthritis; diabetic retinopathy; infertility; obesity;
 KW sleep disorder; neurological degenerative disease; anaemia;
 KW thrombocytopaenia; metastatic tumour; systemic lupus erythematosus;
 KW Fanconi's syndrome.

XX Synthetic.
 OS WO200183525-A2.
 PN 08-NOV-2001.
 XX 02-MAY-2001; 2001WO-US14310.
 XX 03-MAY-2000; 2000US-0563286.
 XX (AMGE-) AMGEN INC.
 XX Feige U, Liu C, Cheetham JC, Boone TC, Gudas JM;
 XX WPI; 2002-130313/17.

XX Novel vehicle-peptide molecule or its multimers useful for treating
 PT inflammatory and autoimmune diseases, cancer, rheumatoid arthritis,
 PT diabetic retinopathy, obesity, sleep disorders and infertility.
 XX Claim 39; Page 62; 176pp; English.

XX The present invention describes a vehicle-peptide molecule (I) or its
 CC multimers. (I) can have antiinflammatory, antitumour, immunosuppressive,
 CC cytostatic, antirheumatic, antiarthritis, antidiabetic, ophthalmological,
 CC antianemic, anorectic, antifertility, haemostatic, dermatological and
 CC neuroprotective activities. (I) can be used as a therapeutic or
 CC prophylactic agent as well as for screening purposes. (I) is useful for
 CC diagnosing diseases characterised by dysfunction of their associated
 CC protein of interest, for identifying normal or abnormal proteins of
 CC interest, as a part of diagnostic kit to detect the presence of their
 CC proteins of interest in a biological sample. Additionally, (I) is useful
 CC for treating inflammatory and autoimmune diseases, tumour growth, cancer,
 CC rheumatoid arthritis, diabetic retinopathy, obesity, sleep disorders,
 CC infertility, and neurological degenerative diseases. (I), comprising
 CC EPO-mimetic compounds are useful for treating disorders characterised by
 CC low red blood cell levels such as anaemia. The TPO-mimetic comprising
 CC compounds are useful for treating conditions that involve an existing

CC megakaryocyte/platelet deficiency or an expected megakaryocyte/platelet
 CC deficiency, such as thrombocytopaenia, aplastic anaemia, metastatic
 CC tumour which result in thrombocytopaenia, systemic lupus erythematosus,
 CC and Fanconi's syndrome. ABB72403 to ABB73426 and ABL35695 to ABL35777
 CC represent amino acid and nucleic acid sequences used in the
 CC exemplification of the present invention.

XX SQ Sequence 10 AA;
 Query Match 68.5%; Score 50; DB 23; Length 10;
 Best Local Similarity 90.0%; Pred. No. 0.011;
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 KDKATFGTHD 10
 ||||| ||
 Db 1 KDKATFGCHD 10

RESULT 14
 AAY82220
 ID AAY82220 standard; Protein; 785 AA.
 XX AC AAY82220;
 DT 12-JUN-2000 (first entry)
 DE Humicola insolens cellobiose dehydrogenase SEQ ID NO:2.
 XX Humicola insolens; cellobiose dehydrogenase; pulp bleaching process.
 KW Humicola insolens.
 OS US6033891-A.
 PN 07-MAR-2000.
 XX 09-MAR-1999; 99US-0265108.
 XX 09-MAR-1999; 99US-0265108.
 XX (NOVO) NOVO NORDISK BIOTECH INC.
 XX Golightly E, Brown K;
 XX WPI; 2000-255698/22.
 XX N-PSDB; AA295701.

XX New cellobiose dehydrogenase polynucleotides and polypeptides used for
 PT modulation of cellobiose dehydrogenase activity
 XX Claim 1; Fig 3; 28pp; English.

XX The present sequence represents cellobiose dehydrogenase isolated from
 CC Humicola insolens. The cellobiose dehydrogenase polynucleotides may be
 CC used to produce recombinant production of the polypeptide. They may also be
 CC used to produce transgenic plants, e.g. monocots such as grasses, sugar
 CC cereals and maize, and dicots such as tobacco, legumes, potato, sugar
 CC beet. A cellobiose dehydrogenase polypeptide deleted cell may also be
 CC produced, which is used for production enzymes and other heterologous
 CC proteins of pharmaceutical interest, such as hormones and growth
 CC factors. The cellobiose dehydrogenase polypeptide may be used in a pulp
 CC bleaching process under alkaline conditions.

XX SQ Sequence 785 AA;
 Query Match 60.3%; Score 44; DB 21; Length 785;
 Best Local Similarity 72.7%; Pred. No. 24;
 Matches 8; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2 DKATFGTHDG 12
 ||||| ||
 Db 188 DTATFGHDNG 198

RESULT 15
AAG65578
ID AAG65578 standard; Protein; 785 AA.
XX
AC AAG65578;
XX
DT 07-JAN-2002 (first entry)
XX
DE H. insolens DSM 1800 cellobiose dehydrogenase polypeptide.
XX
KW Cellobiose dehydrogenase; transgenic; pulp bleaching; cellobiose;
KW pharmaceutical.
XX
OS Humicola insolens.
XX
FH Key Location/Qualifiers
FT Peptide 1..21
FT /note= "signal peptide"
FT Protein 22
FT /note= "mature protein"
XX
PN US6280976-B1.
XX
PD 28-AUG-2001.
XX
PF 05-JAN-2000; 2000US-0479264.
XX
PR 09-MAR-1999; 99US-0265108.
XX
PA (NOVO) NOVOZYMES BIOTECH INC.
XX
PI Golightly EJ, Brown KM;
XX
DR WPI; 2001-601400/68.
DR N-PSDB; AAH47743.
XX
PT Novel nucleic acid encoding polypeptides with cellobiose dehydrogenase
XX activity useful for transgenic plant production
PS Example 2; Fig 3A-C; 27pp; English.
XX
CC The invention relates to nucleic acids encoding polypeptides having
CC cellobiose dehydrogenase activity. Nucleic acid construct the comprising
CC the polynucleotides are useful in transgenic plant production. The
CC encoded protein is useful in pulp bleaching process under alkaline
CC conditions. Plants grown where cellobiose activity has been removed may
CC be used to express heterologous proteins of pharmaceutical interest such
CC as hormones, growth factors and receptors. The present sequence
CC represents a H. insolens DSM 1800 cellobiose dehydrogenase polypeptide.
XX
SQ Sequence 785 AA;
Query Match 60.3%; Score 44; DB 22; Length 785;
Best Local Similarity 72.7%; Pred. No. 24;
Matches 8; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2 DKATFGTHDGG 12
DB 188 DTATFGHDNG 198

Search completed: August 28, 2003, 18:34:29
Job time : 44.2727 secs